Aclaris Therapeutics to Present at Upcoming Investor Conferences
WAYNE, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present at the following conferences:
- Dr. Neal Walker, President and Chief Executive Officer, together with members from the Company’s R&D team, will present a company overview at SVB Leerink’s 13th Annual POLARxPRESS Bus Tour in New York, New York on Thursday, November 21, 2019. The R&D team will include:
- Joseph Monahan, Ph.D. - EVP R&D (Head of Discovery)
- Walter Smith - SVP, R&D
- Paul Changelian, Ph.D. - VP, Biology
- Jon Jacobsen, Ph.D. - VP, Chemistry
- Dr. David Gordon - Chief Medical Officer
- Dr. Walker will also present a company overview at the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019 at 3:05 PM ET at the Four Seasons Hotel in Boston, Massachusetts. A live audio webcast of the presentation may be accessed through the Company's web site, , on the 'Events' section. An archived version of the presentation will be available for 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a physician-led biopharmaceutical company committed to addressing the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company’s diverse and multi-stage portfolio includes one late-stage investigational drug candidate and a pipeline powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit and follow Aclaris on LinkedIn or Twitter @aclaristx.
Aclaris Contact
Michael Tung, M.D.
Corporate Strategy/Investor Relations
484-329-2140
